MedWatch

Novo Nordisk upgrades guidance for the rest of the year

The day before the publication of Novo Nordisk's Q2 report, the company has upgraded its guidance for 2021. Figures from the quarterly report show a positive surprise on the pharmaceutical company's top and bottom lines.

Photo: Tidsvilde Stine/Ritzau Scanpix

Already on Wednesday afternoon, Denmark's largest pharmaceutical company, Novo Nordisk, has disclosed the figures for the second quarter of the year, while the company also upgrades its guidance for the firm's revenue and operating result.

Now, Novo Nordisk expects revenue growth in the range of 10-13 percent after currency adjustments, up against the previous 6-10 percent. As to the operating profit, the firm predicts this will grow between 9-12 percent after currency adjustments, compared with the previous 5-9 percent.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs